Medicaid GLP-1 coverage in Indiana, 2026.

The Healthy Indiana Plan (HIP) does not cover Wegovy for weight loss.

Indiana last reviewed its drug list in 2025-Q4.

Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization (your doctor asks the plan to approve it first).

Coverage summary

IndicationCoverage
Wegovy (weight loss)No
Zepbound (weight loss)No
Ozempic / Mounjaro (type 2 diabetes)Yes
Compounded semaglutide / tirzepatideNo

Prior-authorization criteria

These rules come from the state preferred drug list (PDL), the list of drugs Indiana Medicaid has agreed to pay for.

CriterionValue
PA burdenHigh
BMI threshold (weight-loss path)Not applicable (weight-loss path not covered)
Comorbidity requiredNo
Last PDL update reviewed2025-Q4

What this means in practice

Indiana Medicaid (Hoosier Healthwise and Healthy Indiana Plan) excludes weight-loss GLP-1. Diabetes coverage requires PA with step therapy through metformin.

Managed-care organizations in Indiana

Indiana Medicaid pays private health plans, called managed-care organizations or MCOs, to run its coverage. An MCO has to cover at least what the state list covers and can add rules of its own. Check your own plan's current rules before you send anything in.

  • Anthem Blue Cross and Blue Shield
  • CareSource Indiana
  • MDwise
  • Managed Health Services (Centene)

Cash-pay alternatives if Medicaid does not cover you

If you end up paying cash, the GLP-1 cost guide has what each cash route costs, from the compounded floor to the manufacturer-direct brand prices. For ranked cash-pay options, see programs ranked by price and programs under $150 a month. Manufacturer savings cards and patient-assistance programs are not routes here: federal law bars the cards for anyone on Medicaid, and the free-drug programs require being uninsured.

If a supply gap rather than cost is blocking your refill, the GLP-1 shortage tracker shows which formulations the FDA lists as in shortage now. And if you are 65 or older and also have Medicare, the senior GLP-1 hub lays out the Medicare coverage paths for dual-eligible patients.

For the full cash-pay picture specific to Indiana, see the cheapest GLP-1 in Indiana guide.

19 GLP-1 clinical trials are recruiting in Indiana, and a study supplies its own study medication. Every site is listed on GLP-1 clinical trials in Indiana.

Take it to your prescriber: PA letter library

Indiana has no weight-loss path to appeal into. If you have type 2 diabetes, prior authorization is the route, and the letter library has the template your prescriber signs.

We keep a PA letter library with templates for 13 health plans, Anthem BCBS, Kaiser, Humana, Tricare and FEHB among them, sorted by the 7 clinical pictures that qualify. Each one cites the plan's own policy document, the diagnosis codes it asks for and the clinical trial evidence behind them.

If you have type 2 diabetes plus kidney disease and heart disease, that combination is the strongest case for approval in any state, and the templates cite the three clinical trials behind it.

If your PA is denied, the appeal letter library has denial-specific templates. For the commercial and Medicare coverage paths, see the GLP-1 insurance guide.

Indiana Medicaid GLP-1 FAQ

Does the Healthy Indiana Plan (HIP) cover Wegovy for weight loss?
No. Indiana Medicaid does not cover Wegovy for the weight-loss indication as of the 2025-Q4 preferred drug list review. If you have type 2 diabetes, the diabetes-indicated GLP-1s (Ozempic, Mounjaro) may still be covered with prior authorization.
Does the Healthy Indiana Plan (HIP) cover Zepbound for weight loss?
No. Indiana Medicaid does not cover Zepbound for the weight-loss indication as of the 2025-Q4 preferred drug list review. If you have type 2 diabetes, Mounjaro (tirzepatide, the same molecule as Zepbound) may be covered with prior authorization under the diabetes pathway.
Does the Healthy Indiana Plan (HIP) cover Ozempic or Mounjaro for diabetes?
Yes. Indiana Medicaid covers Ozempic and Mounjaro for type 2 diabetes with prior authorization, usually after a trial of metformin. The diabetes pathway does not carry the BMI threshold that applies to the weight-loss pathway.
What if the Healthy Indiana Plan (HIP) does not cover my GLP-1?
If your GLP-1 is not covered, the routes left do not run through Medicaid. A clinical trial costs nothing and many pay you for your time. Nobody checks your income. Manufacturer savings cards are not a route here, because federal law bars them for anyone on Medicaid. The cheapest route left is cash-pay compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy or Ozempic. The prices checked August 31, 2026 are on the chart. If you were denied, the appeal letter library has denial-specific templates.

Other state Medicaid pages

See the full 51-state coverage table for the side-by-side view across every US state.

How we built this page

Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.

Last updated: 2026-08-28. We check each state Medicaid PDL and PA criteria quarterly. If you have recently had a different experience with Indiana Medicaid, email hello@glpchart.com with the details and we will check it.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.